Impact of erythropoietin on allogenic blood exposure in orthopedic surgery.

Am J Orthop (Belle Mead NJ)

Pharmacy Management Department, CalOptima, Orange, California, USA.

Published: November 2007

Joint reconstruction surgery is associated with significant blood loss, and patients often require perioperative transfusions. Recombinant human erythropoietin (epoetin) can be used in anemic patients scheduled for elective, noncardiac, nonvascular surgery to reduce the need for transfusions. In the study reported here, patients with a preoperative hemoglobin level of 10 to 13 g/dL were treated with epoetin. Our analysis showed that transfusions were given to 3 (8%) of the 38 patients who received epoetin before surgery and 20 (57%) of the 35 historical controls (P<.001) and that length of hospital stay did not differ significantly between the 2 groups. Our results provide further support for use of epoetin as an effective strategy for reducing exposure to allogenic blood in orthopedic surgery.

Download full-text PDF

Source

Publication Analysis

Top Keywords

impact erythropoietin
4
erythropoietin allogenic
4
allogenic blood
4
blood exposure
4
exposure orthopedic
4
surgery
4
orthopedic surgery
4
surgery joint
4
joint reconstruction
4
reconstruction surgery
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!